Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    May 2018
  1. TANG J, Li Y, Sang Y, Yu B, et al
    LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0310.
    PubMed     Text format     Abstract available


  2. GALA K, Li Q, Sinha A, Razavi P, et al
    KMT2C mediates the estrogen dependence of breast cancer through regulation of ERalpha enhancer function.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0273.
    PubMed     Text format     Abstract available


  3. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    PubMed     Text format     Abstract available


  4. ROGERS S, McCloy RA, Parker BL, Gallego-Ortega D, et al
    MASTL overexpression promotes chromosome instability and metastasis in breast cancer.
    Oncogene. 2018 May 10. pii: 10.1038/s41388-018-0295.
    PubMed     Text format     Abstract available


  5. PAREKH A, Das S, Parida S, Das CK, et al
    Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo.
    Oncogene. 2018 May 10. pii: 10.1038/s41388-018-0272.
    PubMed     Text format     Abstract available


  6. BAKER A, Wyatt D, Bocchetta M, Li J, et al
    Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
    Oncogene. 2018 May 10. pii: 10.1038/s41388-018-0251.
    PubMed     Text format     Abstract available


  7. AHIRWAR DK, Nasser MW, Ouseph MM, Elbaz M, et al
    Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation.
    Oncogene. 2018 May 3. pii: 10.1038/s41388-018-0263.
    PubMed     Text format     Abstract available


  8. CHEN A, Sceneay J, Godde N, Kinwel T, et al
    Intermittent hypoxia induces a metastatic phenotype in breast cancer.
    Oncogene. 2018 May 1. pii: 10.1038/s41388-018-0259.
    PubMed     Text format     Abstract available


  9. PAVAN S, Meyer-Schaller N, Diepenbruck M, Kalathur RKR, et al
    A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
    Oncogene. 2018 May 1. pii: 10.1038/s41388-018-0270.
    PubMed     Text format     Abstract available


    April 2018
  10. CHANG JW, Kuo WH, Lin CM, Chen WL, et al
    Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway.
    Oncogene. 2018 Apr 30. pii: 10.1038/s41388-018-0253.
    PubMed     Text format     Abstract available


  11. TOOSI BM, El Zawily A, Truitt L, Shannon M, et al
    EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
    Oncogene. 2018 Apr 27. pii: 10.1038/s41388-018-0228.
    PubMed     Text format     Abstract available


  12. BLANCHETTE-FARRA N, Kita D, Konstorum A, Tesfay L, et al
    Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0243.
    PubMed     Text format     Abstract available


  13. SUN L, Xu X, Chen Y, Zhou Y, et al
    Rab34 regulates adhesion, migration, and invasion of breast cancer cells.
    Oncogene. 2018 Apr 6. pii: 10.1038/s41388-018-0202.
    PubMed     Text format     Abstract available


    March 2018
  14. ZHANG Z, Lin G, Yan Y, Li X, et al
    Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
    Oncogene. 2018 Mar 21. pii: 10.1038/s41388-018-0221.
    PubMed     Text format     Abstract available


  15. LIU X, Bi L, Wang Q, Wen M, et al
    miR-1204 targets VDR to promotes epithelial-mesenchymal transition and metastasis in breast cancer.
    Oncogene. 2018 Mar 20. pii: 10.1038/s41388-018-0215.
    PubMed     Text format     Abstract available


  16. WANG S, Zou Z, Luo X, Mi Y, et al
    LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.
    Oncogene. 2018 Mar 16. pii: 10.1038/s41388-018-0193.
    PubMed     Text format     Abstract available


  17. STEBBING J, Shah K, Lit LC, Gagliano T, et al
    LMTK3 confers chemo-resistance in breast cancer.
    Oncogene. 2018 Mar 15. pii: 10.1038/s41388-018-0197.
    PubMed     Text format     Abstract available


  18. KIM S, Lee E, Jung J, Lee JW, et al
    microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer.
    Oncogene. 2018 Mar 12. pii: 10.1038/s41388-018-0124.
    PubMed     Text format     Abstract available


    February 2018
  19. HE H, Sinha I, Fan R, Haldosen LA, et al
    c-Jun/AP-1 overexpression reprograms ERalpha signaling related to tamoxifen response in ERalpha-positive breast cancer.
    Oncogene. 2018 Feb 22. pii: 10.1038/s41388-018-0165.
    PubMed     Text format     Abstract available


  20. SIRKISOON SR, Carpenter RL, Rimkus T, Anderson A, et al
    Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Oncogene. 2018 Feb 16. pii: 10.1038/s41388-018-0132.
    PubMed     Text format     Abstract available


  21. SAATCI O, Borgoni S, Akbulut O, Durmus S, et al
    Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Oncogene. 2018 Feb 2. pii: 10.1038/s41388-017-0108.
    PubMed     Text format     Abstract available


    January 2018
  22. IRELAND L, Santos A, Campbell F, Figueiredo C, et al
    Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0115.
    PubMed     Text format     Abstract available


  23. BROWNE AL, Charmsaz S, Vareslija D, Fagan A, et al
    Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0042.
    PubMed     Text format     Abstract available


  24. LIANG H, Xiao J, Zhou Z, Wu J, et al
    Hypoxia induces miR-153 through the IRE1alpha-XBP1 pathway to fine tune the HIF1alpha/VEGFA axis in breast cancer angiogenesis.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0089.
    PubMed     Text format     Abstract available


  25. LIAO Y, Xia X, Liu N, Cai J, et al
    Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination.
    Oncogene. 2018 Jan 22. pii: 10.1038/s41388-017-0069.
    PubMed     Text format     Abstract available


  26. ZHANG Y, Wester L, He J, Geiger T, et al
    IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
    Oncogene. 2018 Jan 22. pii: 10.1038/s41388-017-0027.
    PubMed     Text format     Abstract available


  27. NAVANEETHAKRISHNAN S, Rosales JL, Lee KY
    Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0103.
    PubMed     Text format     Abstract available


  28. LEE GH, Yoo KC, An Y, Lee HJ, et al
    FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0114.
    PubMed     Text format     Abstract available


  29. IKINK GJ, Boer M, Bakker ERM, Vendel-Zwaagstra A, et al
    Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
    Oncogene. 2018 Jan 12. pii: 10.1038/s41388-017-0031.
    PubMed     Text format     Abstract available


  30. MARTINEZ-ORDONEZ A, Seoane S, Cabezas P, Eiro N, et al
    Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0036.
    PubMed     Text format     Abstract available


  31. MORATH I, Jung C, Leveque R, Linfeng C, et al
    Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0030.
    PubMed     Text format     Abstract available


    December 2017
  32. PENG F, Wang JH, Fan WJ, Meng YT, et al
    Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
    Oncogene. 2017 Dec 18. pii: onc2017407. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  33. HOWLEY BV, Link LA, Grelet S, El-Sabban M, et al
    A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer.
    Oncogene. 2017 Dec 18. pii: 10.1038/s41388-017-0023.
    PubMed     Text format     Abstract available


  34. HAN B, Zhou B, Qu Y, Gao B, et al
    FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer.
    Oncogene. 2017 Dec 18. pii: 10.1038/s41388-017-0021.
    PubMed     Text format     Abstract available


  35. LUSTIG LC, Dingar D, Tu WB, Lourenco C, et al
    Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
    Oncogene. 2017;36:6830-6837.
    PubMed     Text format     Abstract available


    November 2017
  36. PENG F, Wang JH, Fan WJ, Meng YT, et al
    Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
    Oncogene. 2017 Nov 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    October 2017
  37. LANGER EM, Kendsersky ND, Daniel CJ, Kuziel GM, et al
    ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.
    Oncogene. 2017 Oct 30. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  38. KNOPFOVA L, Biglieri E, Volodko N, Masarik M, et al
    Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding.
    Oncogene. 2017 Oct 30. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  39. LUCANUS AJ, Yip GW
    Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  40. WANG CH, Wang PJ, Hsieh YC, Lo S, et al
    Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  41. XIA L, Xiao X, Liu WL, Song Y, et al
    Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFbeta signaling.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  42. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  43. ROWSON-HODEL AR, Wald JH, Hatakeyama J, O'Neal WK, et al
    Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Oncogene. 2017 Sep 11. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    August 2017
  44. KIM ES, Kim SY, Koh M, Lee HM, et al
    C-reactive protein binds to integrin alpha2 and Fcgamma receptor I, leading to breast cell adhesion and breast cancer progression.
    Oncogene. 2017 Aug 28. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  45. SU CM, Wang MY, Hong CC, Chen HA, et al
    miR-520h is crucial for DAPK2 regulation and breast cancer progression.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  46. WADA M, Canals D, Adada M, Coant N, et al
    P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment.
    Oncogene. 2017 Aug 7. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    July 2017
  47. HEILMANN K, Toth R, Bossmann C, Klimo K, et al
    Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  48. PETERS AA, Jamaludin SYN, Yapa KTDS, Chalmers S, et al
    Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  49. GALLAGHER EJ, Zelenko Z, Neel BA, Antoniou IM, et al
    Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  50. FETTIG LM, McGinn O, Finlay-Schultz J, LaBarbera DV, et al
    Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  51. HERNANDEZ-PEREZ S, Cabrera E, Salido E, Lim M, et al
    DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  52. TANG X, Ding CK, Wu J, Sjol J, et al
    Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  53. SENGUPTA S, Nagalingam A, Muniraj N, Bonner MY, et al
    Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  54. SHAHI P, Wang CY, Chou J, Hagerling C, et al
    GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  55. JALAGUIER S, Teyssier C, Nait Achour T, Lucas A, et al
    Complex regulation of LCoR signaling in breast cancer cells.
    Oncogene. 2017 Apr 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  56. CHEN Y, Zeng C, Zhan Y, Wang H, et al
    Aberrant low expression of p85alpha in stromal fibroblasts promotes breast cancer cell metastasis through exosome-mediated paracrine Wnt10b.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  57. COHEN N, Shani O, Raz Y, Sharon Y, et al
    Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  58. THEWES V, Simon R, Hlevnjak M, Schlotter M, et al
    The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERalpha-negative breast cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  59. FOO TK, Tischkowitz M, Simhadri S, Boshari T, et al
    Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  60. HERNANDEZ-PEREZ S, Cabrera E, Salido E, Lim M, et al
    DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  61. YU L, Di Y, Xin L, Ren Y, et al
    SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  62. WU MJ, Kim MR, Chen YS, Yang JY, et al
    Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCzeta pathway.
    Oncogene. 2017 Feb 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  63. LIN C, Liao W, Jian Y, Peng Y, et al
    CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  64. JHAN JR, Andrechek ER
    Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  65. HE Y, Northey JJ, Pelletier A, Kos Z, et al
    The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.
    Oncogene. 2017 Jan 30. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  66. YANG N, Wang C, Wang Z, Zona S, et al
    FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  67. CRISTOBAL I, Zazo S, Torrejon B, Pedregal M, et al
    CIP2A confirms its prognostic value in triple-negative breast cancer.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format    


  68. ZHOU H, Liu Y, Zhu R, Ding F, et al
    FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  69. FENG J, Li L, Zhang N, Liu J, et al
    Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  70. YU L, Liang Y, Cao X, Wang X, et al
    Identification of MYST3 as a novel epigenetic activator of ERalpha frequently amplified in breast cancer.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  71. HIKEN JF, McDonald JI, Decker KF, Sanchez C, et al
    Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  72. TANG X, Ding CK, Wu J, Sjol J, et al
    Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  73. BLOMME A, Costanza B, de Tullio P, Thiry M, et al
    Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
    Oncogene. 2016 Oct 24. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  74. YANG C, Li Z, Bhatt T, Dickler M, et al
    Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  75. HARROD A, Fulton J, Nguyen VT, Periyasamy M, et al
    Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  76. MIMOTO R, Imawari Y, Hirooka S, Takeyama H, et al
    Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  77. LONE MU, Baghel KS, Kanchan RK, Shrivastava R, et al
    Physical interaction of estrogen receptor with MnSOD: implication in mitochondrial O2.- upregulation and mTORC2 potentiation in estrogen-responsive breast cancer cells.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  78. LIU H, Qiu H, Song Y, Liu Y, et al
    Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  79. LEFORT S, Thuleau A, Kieffer Y, Sirven P, et al
    CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  80. YU PF, Huang Y, Xu CL, Lin LY, et al
    Downregulation of CXCL12 in mesenchymal stromal cells by TGFbeta promotes breast cancer metastasis.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  81. KWAK T, Drews-Elger K, Ergonul A, Miller PC, et al
    Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.
    Oncogene. 2016 Sep 26. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  82. CHANG SS, Yamaguchi H, Xia W, Lim SO, et al
    Aurora A kinase activates YAP signaling in triple-negative breast cancer.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  83. KANG MH, Jeong KJ, Kim WY, Lee HJ, et al
    Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    August 2016
  84. TOMINAGA K, Shimamura T, Kimura N, Murayama T, et al
    Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.
    Oncogene. 2016 Aug 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  85. XU Y, Qin L, Sun T, Wu H, et al
    Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Oncogene. 2016 Aug 15. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    July 2016
  86. YU PF, Huang Y, Han YY, Lin LY, et al
    TNFalpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  87. SAHA SK, Choi HY, Kim BW, Dayem AA, et al
    KRT19 directly interacts with beta-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  88. XU LZ, Li SS, Zhou W, Kang ZJ, et al
    p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  89. FERRER CM, Lu TY, Bacigalupa ZA, Katsetos CD, et al
    O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  90. WERDEN SJ, Sphyris N, Sarkar TR, Paranjape AN, et al
    Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  91. DA MOTTA LL, Ledaki I, Purshouse K, Haider S, et al
    The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  92. RAMADOSS S, Guo G, Wang CY
    Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  93. CAO C, Vasilatos SN, Bhargava R, Fine JL, et al
    Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
    Oncogene. 2016 May 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  94. FARMAKI E, Chatzistamou I, Kaza V, Kiaris H, et al
    A CCL8 gradient drives breast cancer cell dissemination.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  95. HEIN AL, Post CM, Sheinin YM, Lakshmanan I, et al
    RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  96. MENDOZA-VILLANUEVA D, Balamurugan K, Ali HR, Kim SR, et al
    The C/EBPdelta protein is stabilized by estrogen receptor alpha activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  97. TURPIN J, Ling C, Crosby EJ, Hartman ZC, et al
    The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
    Oncogene. 2016 May 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  98. TEO WW, Merino VF, Cho S, Korangath P, et al
    HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24.
    Oncogene. 2016 May 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: